Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2299

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 4
Chunk 2299
---
 relations activities and
other expenses associated with operating as a public company.

Other Income, Net

Other income, net consists predominantly of interest income from interest
bearing bank accounts, interest expense on payables, gains recorded on settlements reached with vendors on payables, and the gain or loss
on the revaluation of earnout and derivative liabilities, which represents the change in fair value of earnout liabilities or outstanding
warrants between periods.

Results of Operations for the years ended December
31, 2024 and 2023

The Results of Operations
for year ended December 31, 2024 are pro forma as the period presented in the following table and discussion includes the Predecessor
for the period from January 1, 2024 through February 13, 2024 and the Company for the period from February 14, 2024 through December 31,
2024. This pro forma period from January 1, 2024 to December 31, 2024 does not include the Merger transactions that occurred on-the-line.

    For the Years Ended December 31,  

    2024  

    (Pro forma) (Predecessor and Successor)  
    2023 (Predecessor)  
    Difference  
    Percentage Change 
  
    Operating expenses: 

    Research and development 
    $7,079,744  
    $5,288,580  
    $1,791,164  
     33.9%
  
    General and administrative 
     9,118,292  
     2,386,469  
     6,731,823  
     282.1%
  
    Total operating expenses 
     16,198,036  
     7,675,049  
     8,522,987  
     111.0%
  
    Loss from operations 
     (16,198,036) 
     (7,675,049) 
     (8,522,987) 
     111.0%

    Other income (expense): 

    Gain from settlement of liabilities with vendor 
     3,339,223  
     8,144  
     3,331,079  
     40,902.2%
  
    Other expense 
     (672,378) 
     (62,182) 
     (610,196)